Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 7/20 | 0.67 |
| ▸ | FAAH | O00519 | 6/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.53 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.52 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.50 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25542915 | 1.00 | NOD1 (0.67) | NOD1FAAHMEN1MAPK1KMT2A | |
| SCHEMBL11294694 | 1.00 | NOD1 (0.67) | NOD1FAAHMEN1MAPK1KMT2A | |
| SCHEMBL14937121 | 0.91 | SLC6A5 (0.67) | NOD1FAAHMEN1KMT2ASLC6A5 | |
| SCHEMBL20272895 | 0.87 | FAAH (0.61) | NOD1FAAHMEN1MAPK1KMT2A | |
| SCHEMBL24443020 | 0.87 | FAAH (0.56) | NOD1FAAHMEN1MAPK1KMT2A | |
| SCHEMBL18699104 | 0.87 | FAAH (0.56) | NOD1FAAHMEN1MAPK1KMT2A | |
| SCHEMBL24443042 | 0.87 | FAAH (0.56) | NOD1FAAHMEN1MAPK1KMT2A | |
| SCHEMBL24443018 | 0.87 | FAAH (0.56) | NOD1FAAHMEN1MAPK1KMT2A | |
| SCHEMBL608666 | 0.85 | FAAH (0.54) | NOD1FAAHMEN1MAPK1KMT2A | |
| SCHEMBL2899382 | 0.85 | FAAH (0.54) | NOD1FAAHMEN1MAPK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3202760-B1 | PEGYLATED LIPIDS AND THEIR USE FOR DRUG DELIVERY | ALNYLAM PHARMACEUTICALS INC (US) | 2019-08-21 | — | — | EP | disclosed |
| US-9999673-B2 | PEGylated lipids and their use for drug delivery | ALNYLAM PHARMACEUTICALS, INC. (US) | 2018-06-19 | — | — | US | disclosed |
| US-9999673-B2 | PEGylated lipids and their use for drug delivery | ALNYLAM PHARMACEUTICALS, INC. (US) | 2018-06-19 | — | — | US | disclosed |
| EP-3202760-A1 | PEGYLATED LIPIDS AND THEIR USE FOR DRUG DELIVERY | Alnylam Pharmaceuticals, Inc. (US) | 2017-08-09 | — | — | EP | disclosed |
| US-20140200257-A1 | PEGYLATED LIPIDS AND THEIR USE FOR DRUG DELIVERY | ALNYLAM PHARMACEUTICALS, INC. (US) | 2014-07-17 | — | — | US | disclosed |
| EP-2663548-A1 | PEGYLATED LIPIDS AND THEIR USE FOR DRUG DELIVERY | Alnylam Pharmaceuticals, Inc. (US) | 2013-11-20 | — | — | EP | disclosed |
| WO-2012099755-A1 | PEGYLATED LIPIDS AND THEIR USE FOR DRUG DELIVERY | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140200257-A1 | PEGYLATED LIPIDS AND THEIR USE FOR DRUG DELIVERY | LIPG, EGFR, LDLR | NOD1 4450/4885FAAH 1542/4885MEN1 2468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.